MediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP Law

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the statement of claim (CV-25-00742450-0000) (the “Claim”) issued by Apollo Technology Capital Corporation (“Apollo”), Nobul Technologies Inc. (“Nobul”), and Regan McGee (together with Apollo and Nobul, the “Plaintiffs”) on May 5, 2025, against MediPharm’s Chief Executive Officer, David Pidduck, and Chairman of the Board, Chris Taves.

Further to the Company’s press release dated May 28, 2025, in which the Company announced that the Plaintiffs agreed to dismiss the frivolous $50 million conflict of interest claim against the Company’s litigation counsel, in its entirety on a with-prejudice basis (the “May 2025 Court Dismissal”), MediPharm is pleased to announce that the Court has now granted the anti-SLAPP motion brought by Mr. Pidduck and Mr. Taves under the “anti-SLAPP” provisions of section 137.1(3) of the Courts of Justice Act (Ontario) (the “Motion”), dismissing the remaining libel allegations against them in full.

The Plaintiffs sought, amongst other things, damages in the amount of $50 million against Mr. Pidduck and Mr. Taves for defamation relating to a letter that was sent to a former executive of a MediPharm subsidiary working alongside Apollo on April 29, 2025 (the “April 29 Letter”), in connection with the proxy contest initiated by the Plaintiffs. In making its decision to grant the Motion, and dismiss all remaining aspects of the Claim in full, the Court noted the following:

“I find that the April 29 Letter is typical of a lawyer's letter that one would expect in these circumstances.”

“In my view there is ample evidence confirming the truth of the assertions/concerns in the April 29 Letter and, again, no evidence to the contrary.”

“I find that the plaintiffs have utterly failed to meet the onus required of them, and I find that the defendants have on balance established valid defences in the case of each of the four defences they assert.”

“The plaintiffs have produced no evidence that the April 29 Letter caused any harm, let alone the "serious harm" that they must show under s. 137.1(4)(b).”

The successful grant of the Motion by the Court today follows both the May 2025 Court Dismissal, and the subsequent dismissal by the Court of the application issued by Apollo and Nobul against the Company on May 16, 2025 relating to, amongst other things, appointing a third-party independent chair to preside over the Annual and Special Meeting of Shareholders of the Company on June 16, 2025 (the “Application”). Costs that are owed to MediPharm as a result of the full dismissal of the Application, have yet to be paid by Apollo and Nobul.